Investing.com - AN2 Therapeutics (NASDAQ: ANTX) reported fourth quarter EPS of $-0.61, $0.02 better than the analyst estimate of $-0.63. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
AN2 Therapeutics's stock price closed at $9.82. It is up 3.04% in the last 3 months and down -34.53% in the last 12 months.
AN2 Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See AN2 Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, AN2 Therapeutics's Financial Health score is "weak performance".
Check out AN2 Therapeutics's recent earnings performance, and AN2 Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar